Carlos Amenabar

Mr. Carlos Amenabar

Autonomous University of Madrid, Madrid, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LJLucia Jimenez
Lucia Jimenez
CACarlos Amenabar
Carlos Amenabar
VMVíctor Mayoral-Varo
Víctor Mayoral-Varo
TMThomas Andrew Mackenzie
Thomas Andrew Mackenzie
MRMaría C. Ramos
María C. Ramos
Wolfgang LinkWolfgang Link
Wolfgang Link
Forkhead box O (FOXO) proteins are transcription factors involved in cancer and aging and their pharmacological manipulation could be beneficial for the treatment of cancer and healthy aging. FOXO proteins are mainly regulated by post-translational modifications including phosphorylation, acetylation and ubiquitination. As these modifications are reversible, activation and inactivation of FOXO factors is attainable through pharmacological treatment. One major regulatory input of FOXO signaling is mediated by protein kinases. Here, we use specific inhibitors against different kinases including PI3K, mTOR, MEK and ALK, and other receptor tyrosine kinases (RTKs) to determine their effect on FOXO3 activity. While we show that inhibition of PI3K efficiently drives FOXO3 into the cell nucleus, the dual PI3K/mTOR inhibitors dactolisib and PI-103 induce nuclear FOXO translocation more potently than the PI3Kδ inhibitor idelalisib. Furthermore, specific inhibition of mTOR kinase activity affecting both mTORC1 and mTORC2 potently induced nuclear translocation of FOXO3, while rapamycin, which specifically inhibits the mTORC1, failed to affect FOXO3. Interestingly, inhibition of the MAPK pathway had no effect on the localization of FOXO3 and upstream RTK inhibition only weakly induced nuclear FOXO3. We also measured the effect of the test compounds on the phosphorylation status of AKT, FOXO3 and ERK, on FOXO-dependent transcriptional activity and on the subcellular localization of other FOXO isoforms. We conclude that mTORC2 is the most important second layer kinase negatively regulating FOXO activity.

29 November 2022 in Traffic
Verified
Journal Article
Open access
LJLucia Jimenez
Lucia Jimenez
VMVictor Mayoral‐Varo
Victor Mayoral‐Varo
CACarlos Amenabar
Carlos Amenabar
JOJudit Ortega
Judit Ortega
JSJoão Sequeira
João Sequeira
Wolfgang LinkWolfgang Link
Wolfgang Link
Chromosomal region maintenance 1 (CRM1 also known as Xpo1 and exportin‐1) is the receptor for the nuclear export controlling the intracellular localization and function of many cellular and viral proteins that play a crucial role in viral infections and cancer. The inhibition of CRM1 has emerged as a promising therapeutic approach to interfere with the lifecycle of many viruses, for the treatment of cancer, and to overcome therapy resistance. Recently, selinexor has been approved as the first CRM1 inhibitor for the treatment of multiple myeloma, providing proof of concept for this therapeutic option with a new mode of action. However, selinexor is associated with dose‐limiting toxicity and hence, the discovery of alternative small molecule leads that could be developed as less toxic anticancer and antiviral therapeutics will have a significant impact in the clinic. Here, we report a CRM1 inhibitor discovery platform. The development of this platform includes reporter cell lines that monitor CRM1 activity by using red fluorescent protein or green fluorescent protein‐labeled HIV‐1 Rev protein with a strong heterologous nuclear export signal. Simultaneously, the intracellular localization of other proteins, to be interrogated for their capacity to undergo CRM1‐mediated export, can be followed by co‐culturing stable cell lines expressing fluorescent fusion proteins. We used this platform to interrogate the mode of nuclear export of several proteins, including PDK1, p110α, STAT5A, FOXO1, 3, 4 and TRIB2, and to screen a compound collection. We show that while p110α partially relies on CRM1‐dependent nuclear export, TRIB2 is exported from the nucleus in a CRM1‐independent manner. Compound screening revealed the striking activity of an organoselenium compound on the CRM1 nuclear export receptor.

21 November 2024
Verified
Book Chapter
Closed access
PDF file
LJLucia Jimenez
Lucia Jimenez
LDLucía Domínguez
Lucía Domínguez
CACarlos Amenabar
Carlos Amenabar
GSGisela Serrão
Gisela Serrão
WLWolfgang Link
Wolfgang Link
Bruno SantosBruno Santos
Bruno Santos

21 November 2024
Verified
Book Chapter
Closed access
PDF file
CACarlos Amenabar
Carlos Amenabar
LJLucia Jimenez
Lucia Jimenez
CMCristiana Mourato
Cristiana Mourato
VMVictor Mayoral-Varo
Victor Mayoral-Varo
DMDiego Megías
Diego Megías
Wolfgang LinkWolfgang Link
Wolfgang Link